Novartis AG has announced an agreement to acquire Regulus Therapeutics for $7.00 per share in cash, with an additional potential payment of $7.00 per share contingent on regulatory approval of Regulus’s lead product candidate, farabursen. This acquisition could reach a total equity value of approximately $1.7 billion if the milestone is achieved. The transaction is expected to close in the second half of 2025, pending customary closing conditions.
Regulus Therapeutics, a biopharmaceutical company specializing in microRNA-targeted medicines, will benefit from Novartis’s global development and commercial capabilities, potentially accelerating the delivery of farabursen to patients with ADPKD. Jay Hagan, CEO of Regulus Therapeutics, expressed excitement about the potential to bring this medicine to patients in need.
Shreeram Aradhye, President of Development and Chief Medical Officer at Novartis, highlighted the significance of farabursen as a potential first-in-class medicine for ADPKD, a common genetic cause of renal failure worldwide.
The tender offer will be initiated by Novartis through a subsidiary, aiming to acquire all outstanding shares of Regulus for $7.00 per share in cash, plus a contingent value right (CVR) for an additional $7.00 per share upon achieving the specified milestone.
— new from PR Newswire